Cover Image
市場調查報告書

創傷:開發平台評估

Wounds - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 255970
出版日期 內容資訊 英文 186 Pages
訂單完成後即時交付
價格
Back to Top
創傷:開發平台評估 Wounds - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 186 Pages
簡介

創傷是因為手術、受傷、化學藥品、熱或冷氣的接觸、摩擦、壓力或是下肢潰瘍和癌症等疾病的影響,造成皮膚及皮下組織受損並引起皮膚保護功能受損(上皮組織的連續性損壞),或皮下接合組織(肌肉、骨骼、神經)受損等。症狀有傷口周圍發紅或是紅色線狀、腫起、分泌出膿狀液體、惡臭、惡寒、發燒等。有服用抗生素等治療法。

本報告網羅全球傷口護理藥開發平台資訊,提供目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的商品評估等。

目錄

簡介

  • 分析範圍

創傷概要

治療藥的開發

  • 創傷開發中產品:概要
  • 創傷開發中產品:比較分析

創傷:正在開發的治療藥:各企業

創傷:正在開發的治療藥:大學·研究機關別

創傷:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

創傷:開發中的產品:各企業

創傷:開發中的產品:大學·研究機關別

創傷:治療藥的開發企業

  • Cardium Therapeutics, Inc.
  • Smith & Nephew Plc
  • Sanofi
  • Biotec Pharmacon ASA
  • Kuros Biosurgery AG
  • Pharming Group N.V.
  • Stratatech Corporation
  • Photopharmica Limited
  • Tissue Repair Company
  • Nanotherapeutics, Inc.
  • Octapharma AG
  • Apricus Biosciences, Inc.
  • Bio3 Research S.r.l
  • NeoStem, Inc.
  • HanAll Biopharma Co., Ltd.
  • Sucampo Pharmaceuticals, Inc.
  • CytoTools AG
  • CYATHUS EXQUIRERE PharmaforschungsGmbH
  • MetrioPharm AG
  • Dongkook Pharmaceutical Co., Ltd.
  • Juventas Therapeutics, Inc.
  • Omnio Healer AB
  • ConjuGon, Inc.
  • Garnet BioTherapeutics
  • Gene Signal International SA
  • AndroScience Corporation
  • GliaMed, Inc.
  • Omeros Corporation
  • NanoBio Corporation
  • FirstString Research, Inc.
  • Molecular Design International, Inc.
  • Sirnaomics, Inc.
  • SunTen Phytotech Co., Ltd.
  • miRagen Therapeutics, Inc.
  • Pacific Northwest Biotechnology, LLC
  • Beech Tree Labs, Inc.
  • Mirrx Therapeutics A/S
  • EyeGene, Inc.
  • Neumedicines Inc.
  • AlgiPharma AS
  • SomaGenics Inc.
  • Advancell
  • Birken AG
  • Provasculon, Inc.
  • Pergamum AB
  • Microbion Corporation
  • Escape Therapeutics, Inc.
  • Kasiak Research Pvt. Ltd.
  • Regenics AS
  • vida therapeutics inc.
  • Hemostemix Ltd

創傷:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • MB-11316
  • dokishisaikurin
  • GAM-501
  • DermaPro CL-05
  • GBT-009
  • HP-802247
  • StrataGraft Skin Tissue
  • KUR-212
  • PPA-904
  • Granexin
  • CSTC-1
  • Evitar
  • JVS-100
  • Mesenchymal Cells For Wound Care
  • Bismuth ethanedithiol
  • MALP-2
  • KUR-213
  • GM-1485
  • CTR-2
  • cobiprostone
  • alprostadil
  • ASCJ-9
  • MDI-301
  • GS-156
  • Soluble Beta Glucan
  • MGN-4220
  • STP-705
  • BTL-slo
  • NB-201
  • RNAi Oligonucleotide To Inhibit VE-Cadherin For Inflammation, Ischemia and Wound Healing
  • NMIL-121
  • Vasculotide
  • AKB-4924
  • Neurotensin
  • C-31510
  • MP-1031
  • Peptides for Dermatology and Infectious Disease
  • CM-101
  • Stem Cell Therapy for Chronic Wound Healing and Scleroderma
  • ANs-31
  • HL-156Fib
  • AlloGraf
  • GN-4474
  • HDFx
  • Drugs to Agonize c-Met for Wound
  • EG-Decorin
  • Bismith-Thiol Compound For Chronic Wound Infection
  • Stem Cell Therapy for Wounds
  • Small Molecule For Acute Wound Care
  • AG-30/5C
  • Recombinant Plasminogen
  • Vernex
  • V-2248
  • Migration Stimulating Factor
  • STD-06
  • Proteins to Inhibit SEB and TSST-1 for Infectious Disease, Infectious Disease, Shock and Respiratory Disorders
  • NL-005
  • hVGF
  • PGF
  • Small Molecule Antagonists to Transforming Growth Factor Beta Receptor for Alopecia, Pulmonary Fibrosis and Dermatology
  • Nu-2
  • PRF-65339
  • A3-APO
  • BCI
  • Chordin
  • Human Soluble CD-146
  • phenytoin
  • pyrvinium chloride
  • Cyathus-1102-B
  • Stem Cell Therapy for Wound Healing
  • DNA Pro-Drug Program
  • Monoclonal Antibody Gel for Inflammation, Burns and Wounds
  • CA5-HIF Gene Therapy for Wound and Ulcers
  • Drug to Inhibit 11ß-HSD1 for Wound Healing
  • Adipose Stem Cell Therapy For Skin Wound
  • Autologous Adipose Stem Cell Therapy for Diabetic Chronic Skin Wound
  • NVN-4428
  • Recombinant Human Collagen Type 1
  • OligoG For Wounds And Burns
  • Small Molecule Targeting LGR6 for Wound Repair and Formation of New Hair Follicles
  • Asiaticoside Derivatives
  • GP-505
  • Enzyme for Dermatology and Infectious Diseases
  • Cell Therapy for Wounds
  • Fibroblast Growth Factor Conjugate
  • PXL-181
  • RNAi Oligonucleotide for Wound Healing
  • Wound Healing Program
  • Sugar-Free Fibroblast Growth Factor
  • Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Musculoskeletal Disorders
  • BCP-01
  • Refaheal
  • Human Growth Factor
  • Recombinant Plasminogen
  • XEN-103
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9422IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H1 2017, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 58, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 7 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 6
  • List of Figures 7
  • Introduction 8
  • Global Markets Direct Report Coverage 8
  • Wounds - Overview 9
  • Wounds - Therapeutics Development 10
  • Pipeline Overview 10
  • Pipeline by Companies 11
  • Pipeline by Universities/Institutes 16
  • Products under Development by Companies 18
  • Products under Development by Universities/Institutes 22
  • Wounds - Therapeutics Assessment 23
  • Assessment by Target 23
  • Assessment by Mechanism of Action 26
  • Assessment by Route of Administration 29
  • Assessment by Molecule Type 31
  • Wounds - Companies Involved in Therapeutics Development 33
  • AlgiPharma AS 33
  • Alliance Pharma Plc 33
  • AmpliPhi Biosciences Corp 33
  • AndroScience Corp 34
  • Anterogen Co Ltd 34
  • Aridis Pharmaceuticals LLC 35
  • Beech Tree Labs Inc 35
  • Bio3 Research Srl 35
  • Biotec Pharmacon ASA 36
  • Blueberry Therapeutics Ltd 36
  • Cellphire Inc 36
  • Chiesi Farmaceutici SpA 37
  • CorMedix Inc 37
  • Dermala Inc 38
  • Destiny Pharma Ltd 38
  • Escape Therapeutics Inc 38
  • EyeGene Inc 39
  • FibroGen Inc 39
  • Foresee Pharmaceuticals LLC 40
  • Gene Signal International SA 40
  • GlaxoSmithKline Plc 40
  • IC-MedTech Inc 41
  • Living Cell Technologies Ltd 41
  • Madam Therapeutics BV 42
  • miRagen Therapeutics Inc 42
  • NatureWise Biotech & Medicals Corp 43
  • Novan Inc 43
  • Octapharma AG 44
  • Omeros Corp 44
  • Osiris Therapeutics Inc 44
  • Pacific Northwest Biotechnology LLC 45
  • ProMetic Life Sciences Inc 45
  • RMB-Research GmbH 46
  • RXi Pharmaceuticals Corp 46
  • SomaGenics Inc 47
  • Stratatech Corp 47
  • Synedgen Inc 47
  • Thesan Pharmaceuticals Inc 48
  • Topadur Pharma AG 48
  • Traverse Biosciences Inc 48
  • Tumorend LLC 49
  • Vascular BioSciences 49
  • viDA Therapeutics Inc 49
  • Wounds - Drug Profiles 51
  • (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 51
  • A-3APO - Drug Profile 52
  • ABSA-01 - Drug Profile 54
  • AGL-110 - Drug Profile 58
  • ALLO-ASC - Drug Profile 59
  • AlloGraf - Drug Profile 61
  • Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 62
  • APO-1 - Drug Profile 63
  • APO-2 - Drug Profile 64
  • AR-101 - Drug Profile 65
  • Arginine Butyrate - Drug Profile 66
  • ARN-077 - Drug Profile 67
  • ASCJ-9 - Drug Profile 68
  • AyuV-25 - Drug Profile 70
  • B-244 - Drug Profile 71
  • BB-1000 - Drug Profile 73
  • BDM-I - Drug Profile 74
  • BTL-slo - Drug Profile 77
  • CAR Peptide - Drug Profile 79
  • Cell Therapy for Dermatology and Immunology - Drug Profile 80
  • CM-101 - Drug Profile 82
  • CRMD-004 - Drug Profile 83
  • CTR-2 - Drug Profile 84
  • daprodustat - Drug Profile 85
  • DB-2121 - Drug Profile 88
  • Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile 89
  • Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile 90
  • Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 91
  • EGS-001 - Drug Profile 92
  • FG-6874 - Drug Profile 93
  • FP-025 - Drug Profile 94
  • G-3KL - Drug Profile 95
  • Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 96
  • Gene Therapy to Activate HSP60 for Wounds - Drug Profile 97
  • GS-156 - Drug Profile 98
  • Human Growth Factor - Drug Profile 99
  • hVGF - Drug Profile 100
  • JM-2 CR - Drug Profile 101
  • LWnt-3a - Drug Profile 102
  • MG-53 - Drug Profile 103
  • MMP-26051 - Drug Profile 105
  • MMP-26052 - Drug Profile 106
  • molgramostim - Drug Profile 107
  • Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 108
  • MRG-110 - Drug Profile 109
  • NBM-67 - Drug Profile 110
  • ND-336 - Drug Profile 111
  • NTCELL - Drug Profile 112
  • Oligomer G for Burn Wounds - Drug Profile 117
  • OTI-1011 - Drug Profile 118
  • OTI-1502 - Drug Profile 119
  • P-148 - Drug Profile 120
  • Panaecin - Drug Profile 121
  • Peptides for Wounds - Drug Profile 122
  • Perlecan - Drug Profile 123
  • PGF - Drug Profile 125
  • plasminogen (recombinant) - Drug Profile 126
  • Polysaccharide for Wounds and Scars - Drug Profile 127
  • Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile 128
  • Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile 129
  • Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 130
  • Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 131
  • Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile 132
  • Recombinant Protein to Agonize FGFR2 for Wounds - Drug Profile 133
  • Recombinant Protein to Agonize NGFR for Wounds - Drug Profile 134
  • Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 135
  • Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 136
  • Recombinant Proteins for Diabetic Wound Healing - Drug Profile 137
  • RT-1740 - Drug Profile 138
  • SFR-9X0125 - Drug Profile 139
  • SG-404 - Drug Profile 140
  • silver sulfadiazine - Drug Profile 141
  • Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile 142
  • Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile 143
  • Small Molecule to Target LGR6 for Dermatology - Drug Profile 144
  • Small Molecules for Staphylococcal Infections and Wounds - Drug Profile 145
  • Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile 146
  • Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 147
  • Soluble Beta Glucan - Drug Profile 148
  • Statmicoll - Drug Profile 151
  • Stm Cell Therapy for Chronic Wounds - Drug Profile 152
  • Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile 153
  • Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 154
  • Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile 155
  • Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 156
  • Thrombosomes - Drug Profile 158
  • Tolecine - Drug Profile 159
  • TOPN-53 - Drug Profile 160
  • TRBN-0224 - Drug Profile 161
  • TWB-103 - Drug Profile 163
  • V-2248 - Drug Profile 164
  • VTI-3000 Series - Drug Profile 165
  • WH-1 - Drug Profile 166
  • XF-70 - Drug Profile 167
  • Wounds - Dormant Projects 168
  • Wounds - Discontinued Products 173
  • Wounds - Product Development Milestones 174
  • Featured News & Press Releases 174
  • Appendix 179
  • Methodology 179
  • Coverage 179
  • Secondary Research 179
  • Primary Research 179
  • Expert Panel Validation 179
  • Contact Us 179
  • Disclaimer 180

List of Tables

  • Number of Products under Development for Wounds, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Wounds - Pipeline by AlgiPharma AS, H1 2017
  • Wounds - Pipeline by Alliance Pharma Plc, H1 2017
  • Wounds - Pipeline by AmpliPhi Biosciences Corp, H1 2017
  • Wounds - Pipeline by AndroScience Corp, H1 2017
  • Wounds - Pipeline by Anterogen Co Ltd, H1 2017
  • Wounds - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
  • Wounds - Pipeline by Beech Tree Labs Inc, H1 2017
  • Wounds - Pipeline by Bio3 Research Srl, H1 2017
  • Wounds - Pipeline by Biotec Pharmacon ASA, H1 2017
  • Wounds - Pipeline by Blueberry Therapeutics Ltd, H1 2017
  • Wounds - Pipeline by Cellphire Inc, H1 2017
  • Wounds - Pipeline by Chiesi Farmaceutici SpA, H1 2017
  • Wounds - Pipeline by CorMedix Inc, H1 2017
  • Wounds - Pipeline by Dermala Inc, H1 2017
  • Wounds - Pipeline by Destiny Pharma Ltd, H1 2017
  • Wounds - Pipeline by Escape Therapeutics Inc, H1 2017
  • Wounds - Pipeline by EyeGene Inc, H1 2017
  • Wounds - Pipeline by FibroGen Inc, H1 2017
  • Wounds - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
  • Wounds - Pipeline by Gene Signal International SA, H1 2017
  • Wounds - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Wounds - Pipeline by IC-MedTech Inc, H1 2017
  • Wounds - Pipeline by Living Cell Technologies Ltd, H1 2017
  • Wounds - Pipeline by Madam Therapeutics BV, H1 2017
  • Wounds - Pipeline by miRagen Therapeutics Inc, H1 2017
  • Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H1 2017
  • Wounds - Pipeline by Novan Inc, H1 2017
  • Wounds - Pipeline by Octapharma AG, H1 2017
  • Wounds - Pipeline by Omeros Corp, H1 2017
  • Wounds - Pipeline by Osiris Therapeutics Inc, H1 2017
  • Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017
  • Wounds - Pipeline by ProMetic Life Sciences Inc, H1 2017
  • Wounds - Pipeline by RMB-Research GmbH, H1 2017
  • Wounds - Pipeline by RXi Pharmaceuticals Corp, H1 2017
  • Wounds - Pipeline by SomaGenics Inc, H1 2017
  • Wounds - Pipeline by Stratatech Corp, H1 2017
  • Wounds - Pipeline by Synedgen Inc, H1 2017
  • Wounds - Pipeline by Thesan Pharmaceuticals Inc, H1 2017
  • Wounds - Pipeline by Topadur Pharma AG, H1 2017
  • Wounds - Pipeline by Traverse Biosciences Inc, H1 2017
  • Wounds - Pipeline by Tumorend LLC, H1 2017
  • Wounds - Pipeline by Vascular BioSciences, H1 2017
  • Wounds - Pipeline by viDA Therapeutics Inc, H1 2017
  • Wounds - Dormant Projects, H1 2017
  • Wounds - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Wounds - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Wounds - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Wounds - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Wounds - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Wounds, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top